NCT06175143View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

GR2002 injection

TSLP monoclonal antibody

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY